Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10)

The summary for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10): Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), National Institutes of Health, invites applications from investigators willing to participate under a cooperative agreement as Core Clinical Centers in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a collaborative multicenter clinical program that promotes the efficient comparison of novel treatment approaches and management strategies for potential benefit of children and adults undergoing hematopoietic stem cell transplantation. This is an open competition for the renewal of an existing network. Mechanism of Support. This FOA will utilize the U10 NIH Cooperative Clinical Research Agreement grant mechanism. Funds Available and Anticipated Number of Awards. NHLBI and NCI intend to commit up to $63.5 million over six years to fund up to 19 Core Clinical Centers with expertise in hematopoietic stem cell transplantation (HSCT) and a Data Coordinating Center (DCC) to support the program. Investigators interested in applying as DCC for the BMT CTN program should refer to the companion Request for Applications (RFA-HL-11-028).

Federal Grant Title:	Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-11-013
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Cancer Treatment Research
Current Application Deadline:	Oct 13, 2010
Original Application Deadline:	Oct 13, 2010
Posted Date:	Aug 11, 2010
Creation Date:	Aug 11, 2010
Archive Date:	Nov 13, 2010
Total Program Funding:
Maximum Federal Grant Award:	$115,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) .
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...